t
Roquefort Therapeutics plc announced on June 27, 2024, that all resolutions proposed at its Annual General Meeting (AGM) were duly passed by shareholders. Resolutions 1 through 6 were passed with 100% of votes cast in favour, and resolutions 7 and 8 passed with 99.96% of votes cast in favour. A total of 19.3% of the Company's voting capital, representing 129,149,998 ordinary shares in issue on June 25, 2024, was instructed for the resolutions.
| Date | 27 Jun 2024 |
| Time | 12:46:12 |
| Category | AGMs and other meetings |
| ID | 1942U |
27 June 2024
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Results of AGM
Roquefort Therapeutics (LSE:ROQ, OTCQB: ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth immuno-oncology market, is pleased to announce that at the Company's Annual General Meeting ("AGM") held earlier today, all resolutions proposed were duly passed.
The resolutions were put to shareholders via a poll, the results of which were as follows:
|
Resolution |
Poll Results |
Total Votes Withheld* |
|||
|
For |
Against |
Total Votes Cast |
|||
|
1 |
Shares |
24,948,663 |
- |
24,948,663 |
- |
|
% |
100.00% |
- |
|||
|
2 |
Shares |
24,943,456 |
- |
24,943,456 |
5,191 |
|
% |
100.00% |
- |
|||
|
3 |
Shares |
24,943,472 |
- |
24,943,472 |
5,191 |
|
% |
100.00% |
- |
|||
|
4 |
Shares |
20,529,178 |
- |
20,529,178 |
4,419,485 |
|
% |
100.00% |
- |
|||
|
5 |
Shares |
24,948,663 |
- |
24,948,663 |
- |
|
% |
100.00% |
- |
|||
|
6 |
Shares |
24,948,663 |
- |
24,948,663 |
- |
|
% |
100.00% |
- |
|||
|
7 |
Shares |
24,938,750 |
9,913 |
24,948,663 |
- |
|
% |
99.96% |
0.04% |
|||
|
8 |
Shares |
24,938,730 |
9,933 |
24,948,663 |
- |
|
% |
99.96% |
0.04% |
|||
* Votes withheld are not counted in the calculation of the proportion of votes for and against a resolution.
The total number of ordinary shares in issue on 25 June 2024, the deadline for casting votes by proxy in advance of the AGM, was 129,149,998 shares. 19.3% of voting capital was instructed in respect of the resolutions put to the AGM.
|
Roquefort Therapeutics plc |
+44 (0)20 3918 8633 |
|
Stephen West (Chairman) / Ajan Reginald (CEO) |
|
|
SP Angel Corporate Finance LLP (Broker) Jeff Keating / David Hignell / Vadim Alexandre |
+44 (0) 20 3470 0470
|
|
Buchanan (Public Relations) Ben Romney / Jamie Hooper / George Beale |
+44 (0)20 7466 5000
|
|
Peak IR (Investor Relations) Seb Wykeham |
+33 (0)7 44 44 15 42 |
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth immuno-oncology segment prior to partnering or selling to big pharma.
Roquefort Therapeutics' portfolio consists of five novel, patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of:
· Midkine antibodies with significant in vivo efficacy and toxicology studies;
· Midkine RNA therapeutics with novel anti-cancer gene editing action;
· Midkine mRNA therapeutics with novel anti-cancer approach;
· STAT-6 siRNA therapeutics targeting solid tumours with significant in vivo efficacy; and
· MK cell therapy with direct and NK-mediated anti-cancer action
For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on X (formerly Twitter).